- Recipharm has announced a multi-million investment in a new Blow-Fill-Seal (BFS) manufacturing line to expand capacity for customer programs from development through commercial supply.
- The new capacity will support ophthalmic products and complements Recipharm’s existing BFS capabilities across biologics, small molecules, and vaccines.
Recipharm has announced a multi-million investment in a new Blow-Fill-Seal (BFS) manufacturing line aimed at expanding capacity for customer programs from development through commercial supply. The CDMO said the investment builds on its 50 years of experience in BFS technology and supports its sterile drug product development and contract manufacturing services.
The expanded capacity is intended to support a range of ophthalmic product programs. Recipharm said the new manufacturing line will be supported by local execution teams and its global network of technical experts.
According to the company, its BFS capabilities span pilot-scale manufacturing for feasibility studies and early-stage supply, clinical-scale manufacturing for small batches and stability studies, and commercial-scale production. These capabilities are designed to support products as they move through development toward commercial supply.
“Customers need sterile manufacturing partners that can combine technical expertise, operational scale and reliable delivery. This investment expands Recipharm’s BFS capacity, strengthens our technical offering and positions Recipharm to meet growing customer demand with the speed, scale and quality required for today’s complex product programmes.”
Greg Behar, Chief Executive Officer of Recipharm
Recipharm said its BFS platform supports biologics, small molecules, ophthalmic products, and vaccines. The company also offers specialized manufacturing environments for oxygen- and temperature-sensitive formulations. Recipharm noted that BFS technology uses fully automated aseptic processing to help reduce contamination risk and may provide supply chain, cost, and environmental benefits compared with traditional glass filling processes.
